Safety and efficacy of tandem 131 I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of tandem 131 I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma

Published:2011-04-14 Issue:7 Volume:57 Page:1124-1129
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr. Blood Cancer

Author:

Johnson Kelsey,McGlynn Barbara,Saggio Jennifer,Baniewicz Diane,Zhuang Hongming,Maris John M.,Mosse Yael P.

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.23062/fullpdf

Reference16 articles.

1. Neuroblastoma;Maris;Lancet,2007

2. Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for neuroblastoma;Yu;NEJM,2010

3. 131I-metaiodobenzylguanidine (131I- MIBG) therapy for residual neuroblastoma: A mono-institutional experience with 43 patients;Garaventa;Br J Cancer,1999

4. Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma;Hutchinson;J Nucl Biol Med,1991

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 131I-mIBG Therapy in the Management of High-Risk Neuroblastoma: A Retrospective Study from a Tertiary Level Hospital in South India;Indian Journal of Medical and Paediatric Oncology;2024-07-18

2. A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastoma;EJC Paediatric Oncology;2024-06

3. Solid Tumours;The EBMT Handbook;2024

4. The Impact of 131I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma;Children;2023-12-18

5. Reaching the target dose with one single ¹³¹I‐mIBG administration in high‐risk neuroblastoma: The determinant impact of the primary tumour;Pediatric Blood & Cancer;2023-12-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3